Six The phosphodiesterase-five inhibitor sildenafil is licensed for PAH in FC I–IV in the United states and FC II–III in Europe. Endothelin receptor antagonists (ERAs) which include bosentan, sitaxentan and ambrisentan are oral therapies licensed to be used in PAH. As no oral agent has revealed superiority there stays discussion https://sergionedzk.idblogz.com/26489390/top-bosentan-secrets